Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Similar to the advent of target therapy, immune checkpoint inhibitors (ICIs) are rapidly shifting the oncological landscape and profoundly transforming clinical cancer care, in particular in non-small cell lung cancer (NSCLC) [1,2].

Source: Lung Cancer - August 1, 2020 Category: Cancer & Oncology Authors: G. Mazzaschi, R. Minari, A. Zecca, A. Cavazzoni, V. Ferri, C. Mori, A. Squadrilli, P. Bordi, S. Buti, M. Bersanelli, A. Leonetti, A Cosenza, L. Ferri, E. Rapacchi, G. Missale, P.G. Petronini, F. Quaini, M Tiseo Source Type: research